Diabetes Mellitus, Type 1NCT04655131
Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus
A study testing Whey protein isolate in people with Diabetes Mellitus, Type 1 and Hyperglycemia, Postprandial, run by University Hospitals Cleveland Medical Center at 1 site in United States.
Trial summary
In type 1 Diabetes Mellitus, patients receive insulin doses if they consume specific amounts of carbohydrates. Currently, insulin is not being administered for consumption of protein although studies in adults show that consuming about 75 grams of protein causes elevation in post prandial glucose levels and might need… Read more about this study
- Who is it for?
- Ages 5 to 17 years
- Conditions the study is for
- Diabetes Mellitus, Type 1, Hyperglycemia, Postprandial
- What is being tested?
- Whey protein isolate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Jun 2018to 25 Nov 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- . Duration of type 1 diabetes for > 1year.
- On insulin pump or multiple daily injection regimen
- Uses a personal Dexcom CGM
- Age: 5- 17 years
- HbA1C range: < 9%
Who cannot join
- Hyperlipidemia
- Diabetic gastroparesis
- Dietary restrictions
- Celiac disease and other malabsorption syndromes
- Uncontrolled hypothyroidism
- Chronic use of steroids or antipsychotics
Show all 9Show fewer
- Metabolic disorders of gluconeogenesis
- Use of oral hypoglycemic agents
- Participating in another clinical trial
Trial locations and contacts
1 site in 1 country.
United States1 site
University Hospitals Cleveland medical Center
Cleveland, Ohio, 44106
About this study
In type 1 Diabetes Mellitus, patients receive insulin doses if they consume specific amounts of carbohydrates. Currently, insulin is not being administered for consumption of protein although studies in adults show that consuming about 75 grams of protein causes elevation in post prandial glucose levels and might need insulin coverage. We are proposing that this amount is different for kids and it might vary based on weight, age, pubertal stage, HbA1C or other factors.
This has not been studied in children before, and it will provide information about the amount of protein in the diet that can cause elevation in post prandial glucose.
Read the detailed description
In target glycemic control in children with type 1 diabetes (T1D) continues to be a challenge despite advances in methods of insulin delivery and medical knowledge in this area. One of the major aspects is controlling postprandial glycemia (PPG). The relationship between dietary intake of carbohydrates and PPG is well established, and the use of insulin coverage for carbohydrate intake is standard of care. Insulin dose for carbohydrate coverage increases with body weight and progression through puberty. Multiple researchers have attempted to study the effect of dietary intake of protein and fat on PPG as well, but this relationship is not well established in the pediatric age group and there are not clear guidelines for patients on when and how to give insulin for protein intake.
Meals with high protein content have been shown to cause higher glucose excursions in patients with T1D, and lower glycemic response in healthy individuals which suggests that physiologic response to protein intake involves higher insulin secretion. This has also been demonstrated by Sun et al, where they showed an increase in insulinemic index in healthy individuals when consuming chicken with rice compared to rice alone.
The effect of dietary protein in individuals with T1D has been studied in mixed meals several times. Smart et al demonstrated that the greatest glucose excursions after high protein low fat meal occurred most significantly form min 150 to 300 after the meal, when insulin is given to cover carbohydrates only. In 2013, Borie-Swinburne et al measured interstitial glucose levels by CGM in 28 c-peptide negative T1D patients, on two consecutive nights, with and without addition of 21.5 grams of protein to dinner (40 g vs 61.5 g). They concluded that no additional insulin is needed to cover for the added protein. Neu et al studied 15 adolescents with T1D on two consecutive nights. They used CGM monitoring for 12 hours, and they compared the area under the curve (AUC) between regular meals and fat/ protein rich meal. They found a significant difference and they recommended additional insulin for fat /protein rich meals.
Investigating the effect of protein-only intake is also an area of research focus. Paterson et al studied 27 patients with TID , aged 7-40 yrs, where they were given 6 test meals of varying amounts (0g, 12.5g, 25g, 50g, 75g and 100g) of pure protein without giving insulin. Postprandial glycemia was found to be significantly higher only for 75 and 100 grams of protein compared to the lower quantities. Glucose levels were slower to rise when compared to consumption of 20 grams of carbohydrates. Paterson et al also conducted another study with slightly different design: 27 participants with T1D [aged 10-40 years, HbA1c ≤ 64 mmol/mol (8%), BMI ≤ 91st percentile] received a 30-g carbohydrate (negligible fat) test drink with a variable amount of protein daily over 5 days in randomized order. Protein (whey isolate 0 g/kg carbohydrate, 0 g/kg lipid) was added in amounts of 0 (control), 12.5, 25, 50 and 75 g. A standardized dose of insulin was given for the carbohydrate. PPG was assessed by 5 hours of continuous glucose monitoring. Increasing protein quantity in a low-fat meal containing consistent amounts of carbohydrate decreases glucose excursions in the early (0-60-min) postprandial period and then increases in the later postprandial period in a dose-dependent manner. In summary, Paterson et al concluded that there was a threshold for dietary protein intake (75 grams), and only protein intake above this threshold regardless of body weight would result in post prandial hyperglycemia. However, these studies included a wide range of ages and did not adjust for body weight in their analysis.
- Innovation The purpose of this study is to explore the role of weight in the relationship between protein intake and post prandial glucose (PPG) levels. The study design (36 children each receiving 6 increasing nominal doses of protein) allows for the relationship to be studied both across patients of varying weights within each nominal dose, and across patients (whose weights remain the same) across the increasing doses.
Our aims:
Aim 1: To describe the relationship of weight (in kg), and mg of protein per kg body weight, to PPG, graphically and statistically, at each nominal dose. The heaviest children will receive the lowest mg/kg amount of protein at each nominal dose, so these relationships with PPG will be inverse. Additionally, children with different weights and receiving different nominal doses, may be receiving the same mg/kg protein. Observing all nominal doses together will allow us to determine whether the relationship, if any, is linear, demonstrates a threshold, or exhibits a doseresponse curve, as examples.
Aim 2: To describe graphically and statistically the relationship of dose of protein to PPG by patient across increasing doses. Since the weight remains constant (or approximately constant) within a patient, adjustment by weight would yield the same results. The expectation is that these results will confirm those from Aim 1.
Aim 3: To construct a multivariate mixed model where any observed relationships can be controlled for other demographic and clinical characteristics possibly associated with blood glucose levels. The type of model will depend on the results of Aims 1 and 2.
- Being tested
- Whey protein isolate
- Medical subject headings
- Diabetes Mellitus, Type 1, Hyperglycemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Whey protein isolateDietary supplement
Commercially available, FDA approved whey protein isolate for dietary supplementation
| Study group | Role | What they receive |
|---|---|---|
| Protein consumption : 0 gm | Active comparator | Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate Receives: Dietary Supplement: Whey protein isolate |
| Protein consumption : 12.5 gm | Experimental | Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate Receives: Dietary Supplement: Whey protein isolate |
| Protein consumption : 25 gm | Experimental | Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate Receives: Dietary Supplement: Whey protein isolate |
| Protein consumption :37.5 gm | Experimental | Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate Receives: Dietary Supplement: Whey protein isolate |
| Protein consumption : 50 gm | Experimental | Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate Receives: Dietary Supplement: Whey protein isolate |
| Protein consumption : 62.5 gm | Experimental | Participant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate Receives: Dietary Supplement: Whey protein isolate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of positive events for each protein amount.
Events of postprandial hyperglycemia were defined as rise in glucose >50 mg/dL compared to baseline
Measured: from hour 0 to hour 5 after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Dec 2020
- Study start18 Jun 2018
- Primary completion25 Nov 2018
- Study completion25 Nov 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 1Studies of the same condition, open and under way.
- More trials run by University Hospitals Cleveland Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dalia Dalle, University Hospitals Cleveland Medical Center
- Investigators
- Dalia Dalle, MD, Principal investigator, University Hospitals Cleveland Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04655131
- Sponsor's protocol ID
- 01-18-18
- Status last verified
- Dec 2020
- First submitted
- 22 Nov 2020
- Last updated
- 7 Dec 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus
- ClinicalTrials.gov ID
- NCT04655131
- Acronym / sponsor ID
- 01-18-18
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 11 participants (actual)
- Lead sponsor
- University Hospitals Cleveland Medical CenterUniversity, hospital or other
- Study start
- 18 Jun 2018 (actual)
- Primary completion
- 25 Nov 2018 (actual)
- Study completion
- 25 Nov 2018 (actual)
- First posted
- 7 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In type 1 Diabetes Mellitus, patients receive insulin doses if they consume specific amounts of carbohydrates. Currently, insulin is not being administered for consumption of protein although studies in adults show that consuming about 75 grams of protein causes elevation in post prandial glucose levels and might need insulin coverage. We are proposing that this amount is different for kids and it might vary based on weight, age, pubertal stage, HbA1C or other factors.
This has not been studied in children before, and it will provide information about the amount of protein in the diet that can cause elevation in post prandial glucose.
Detailed description
In target glycemic control in children with type 1 diabetes (T1D) continues to be a challenge despite advances in methods of insulin delivery and medical knowledge in this area. One of the major aspects is controlling postprandial glycemia (PPG). The relationship between dietary intake of carbohydrates and PPG is well established, and the use of insulin coverage for carbohydrate intake is standard of care. Insulin dose for carbohydrate coverage increases with body weight and progression through puberty. Multiple researchers have attempted to study the effect of dietary intake of protein and fat on PPG as well, but this relationship is not well established in the pediatric age group and there are not clear guidelines for patients on when and how to give insulin for protein intake.
Meals with high protein content have been shown to cause higher glucose excursions in patients with T1D, and lower glycemic response in healthy individuals which suggests that physiologic response to protein intake involves higher insulin secretion. This has also been demonstrated by Sun et al, where they showed an increase in insulinemic index in healthy individuals when consuming chicken with rice compared to rice alone.
The effect of dietary protein in individuals with T1D has been studied in mixed meals several times. Smart et al demonstrated that the greatest glucose excursions after high protein low fat meal occurred most significantly form min 150 to 300 after the meal, when insulin is given to cover carbohydrates only. In 2013, Borie-Swinburne et al measured interstitial glucose levels by CGM in 28 c-peptide negative T1D patients, on two consecutive nights, with and without addition of 21.5 grams of protein to dinner (40 g vs 61.5 g). They concluded that no additional insulin is needed to cover for the added protein. Neu et al studied 15 adolescents with T1D on two consecutive nights. They used CGM monitoring for 12 hours, and they compared the area under the curve (AUC) between regular meals and fat/ protein rich meal. They found a significant difference and they recommended additional insulin for fat /protein rich meals.
Investigating the effect of protein-only intake is also an area of research focus. Paterson et al studied 27 patients with TID , aged 7-40 yrs, where they were given 6 test meals of varying amounts (0g, 12.5g, 25g, 50g, 75g and 100g) of pure protein without giving insulin. Postprandial glycemia was found to be significantly higher only for 75 and 100 grams of protein compared to the lower quantities. Glucose levels were slower to rise when compared to consumption of 20 grams of carbohydrates. Paterson et al also conducted another study with slightly different design: 27 participants with T1D [aged 10-40 years, HbA1c ≤ 64 mmol/mol (8%), BMI ≤ 91st percentile] received a 30-g carbohydrate (negligible fat) test drink with a variable amount of protein daily over 5 days in randomized order. Protein (whey isolate 0 g/kg carbohydrate, 0 g/kg lipid) was added in amounts of 0 (control), 12.5, 25, 50 and 75 g. A standardized dose of insulin was given for the carbohydrate. PPG was assessed by 5 hours of continuous glucose monitoring. Increasing protein quantity in a low-fat meal containing consistent amounts of carbohydrate decreases glucose excursions in the early (0-60-min) postprandial period and then increases in the later postprandial period in a dose-dependent manner. In summary, Paterson et al concluded that there was a threshold for dietary protein intake (75 grams), and only protein intake above this threshold regardless of body weight would result in post prandial hyperglycemia. However, these studies included a wide range of ages and did not adjust for body weight in their analysis.
- Innovation The purpose of this study is to explore the role of weight in the relationship between protein intake and post prandial glucose (PPG) levels. The study design (36 children each receiving 6 increasing nominal doses of protein) allows for the relationship to be studied both across patients of varying weights within each nominal dose, and across patients (whose weights remain the same) across the increasing doses.
Our aims:
Aim 1: To describe the relationship of weight (in kg), and mg of protein per kg body weight, to PPG, graphically and statistically, at each nominal dose. The heaviest children will receive the lowest mg/kg amount of protein at each nominal dose, so these relationships with PPG will be inverse. Additionally, children with different weights and receiving different nominal doses, may be receiving the same mg/kg protein. Observing all nominal doses together will allow us to determine whether the relationship, if any, is linear, demonstrates a threshold, or exhibits a doseresponse curve, as examples.
Aim 2: To describe graphically and statistically the relationship of dose of protein to PPG by patient across increasing doses. Since the weight remains constant (or approximately constant) within a patient, adjustment by weight would yield the same results. The expectation is that these results will confirm those from Aim 1.
Aim 3: To construct a multivariate mixed model where any observed relationships can be controlled for other demographic and clinical characteristics possibly associated with blood glucose levels. The type of model will depend on the results of Aims 1 and 2.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Protein consumption : 0 gm | Active comparator | Dietary Supplement: Whey protein isolateParticipant's glucose levels are monitored from hour 0 to hour 5 after consumption of 0 gm of whey protein isolate |
| Protein consumption : 12.5 gm | Experimental | Dietary Supplement: Whey protein isolateParticipant's glucose levels are monitored from hour 0 to hour 5 after consumption of 12.5 gm of whey protein isolate |
| Protein consumption : 25 gm | Experimental | Dietary Supplement: Whey protein isolateParticipant's glucose levels are monitored from hour 0 to hour 5 after consumption of 25 gm of whey protein isolate |
| Protein consumption :37.5 gm | Experimental | Dietary Supplement: Whey protein isolateParticipant's glucose levels are monitored from hour 0 to hour 5 after consumption of 37.5 gm of whey protein isolate |
| Protein consumption : 50 gm | Experimental | Dietary Supplement: Whey protein isolateParticipant's glucose levels are monitored from hour 0 to hour 5 after consumption of 50 gm of whey protein isolate |
| Protein consumption : 62.5 gm | Experimental | Dietary Supplement: Whey protein isolateParticipant's glucose levels are monitored from hour 0 to hour 5 after consumption of 62.5 gm of whey protein isolate |
Who may qualify
- Ages
- 5 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- . Duration of type 1 diabetes for > 1year.
- On insulin pump or multiple daily injection regimen
- Uses a personal Dexcom CGM
- Age: 5- 17 years
- HbA1C range: < 9%
Key exclusion criteria (9 listed)
- Hyperlipidemia
- Diabetic gastroparesis
- Dietary restrictions
- Celiac disease and other malabsorption syndromes
- Uncontrolled hypothyroidism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Whey protein isolateCommercially available, FDA approved whey protein isolate for dietary supplementation | Dietary supplement | Protein consumption : 0 gm, Protein consumption : 12.5 gm, Protein consumption : 25 gm, Protein consumption : 50 gm, Protein consumption : 62.5 gm, Protein consumption :37.5 gm |
Primary outcome
Number of positive events for each protein amount.
Time frame: from hour 0 to hour 5 after intervention
Events of postprandial hyperglycemia were defined as rise in glucose >50 mg/dL compared to baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Dec 2020.
- Individual participant dataSharing planned: No
Related trials for Diabetes Mellitus, Type 1
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dalia Dalle, MD principal investigator
University Hospitals Cleveland Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Whey protein isolate in people with Diabetes Mellitus, Type 1 and Hyperglycemia, Postprandial, run by University Hospitals Cleveland Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of positive events for each protein amount. (time frame: from hour 0 to hour 5 after intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Dec 2020.